MX2023002674A - Vacuna del tallo de ha para blancos positivos a anticuerpos ha. - Google Patents
Vacuna del tallo de ha para blancos positivos a anticuerpos ha.Info
- Publication number
- MX2023002674A MX2023002674A MX2023002674A MX2023002674A MX2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A MX 2023002674 A MX2023002674 A MX 2023002674A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine
- influenza virus
- vector
- disease
- against influenza
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000712461 unidentified influenza virus Species 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000013613 expression plasmid Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a vacunas contra la infección o enfermedad por el virus de la influenza para blancos con anticuerpos preexistentes contra el dominio de cabeza HA del virus de la influenza. La invención se refiere a un vector recombinante que expresa un polipéptido del tallo de HA, una vacuna que comprende el vector o una célula hospedera con dicho vector, usos del vector, la célula hospedera o la vacuna, y métodos para reducir la infección o enfermedad por el virus de la influenza. El vector recombinante puede ser un ácido nucleico tal como un plásmido de expresión eucariota o un ARN, un virus o una partícula de replicón (RP). Esta vacunación permite la inducción de una respuesta inmunitaria temprana y eficaz contra la infección o enfermedad inducida por el virus de la influenza, no obstaculizada por anticuerpos anti-dominio de cabeza HA preexistentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20194937 | 2020-09-07 | ||
PCT/EP2021/074446 WO2022049276A1 (en) | 2020-09-07 | 2021-09-06 | Ha stem vaccine for ha antibody-positive targets |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002674A true MX2023002674A (es) | 2023-04-03 |
Family
ID=72428193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002674A MX2023002674A (es) | 2020-09-07 | 2021-09-06 | Vacuna del tallo de ha para blancos positivos a anticuerpos ha. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240024456A1 (es) |
EP (1) | EP4210740A1 (es) |
JP (1) | JP2023539771A (es) |
KR (1) | KR20230065321A (es) |
CN (1) | CN116528893A (es) |
BR (1) | BR112023004123A2 (es) |
CA (1) | CA3190070A1 (es) |
MX (1) | MX2023002674A (es) |
WO (1) | WO2022049276A1 (es) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5961982A (en) | 1985-09-06 | 1999-10-05 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
FR2749022B1 (fr) | 1996-05-23 | 2001-06-01 | Rhone Merieux | Cellules aviaires immortelles |
US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
AU2005245956B2 (en) | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
CA2638746C (en) | 2006-03-15 | 2014-12-02 | Intervet International B.V. | Recombinant mononegaviral virus vectors |
PL2947149T3 (pl) | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
KR20130075732A (ko) | 2010-03-30 | 2013-07-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
HUE033739T2 (en) | 2010-10-18 | 2018-01-29 | Intervet Int Bv | Turkey herpesvirus vector vaccine against avian influenza in poultry |
ES2582324T3 (es) | 2011-05-27 | 2016-09-12 | 20Med Therapeutics B.V. | Nanogeles |
MX357009B (es) | 2011-11-28 | 2018-06-22 | Crucell Holland Bv | Vacunas contra el virus de la influenza y sus usos. |
WO2016005482A1 (en) * | 2014-07-10 | 2016-01-14 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
US10428316B2 (en) | 2014-12-04 | 2019-10-01 | Intervet Inc. | Immortalised chicken embryo fibroblasts |
AR103245A1 (es) | 2014-12-24 | 2017-04-26 | Intervet Int Bv | Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada |
US20200323975A1 (en) | 2017-12-04 | 2020-10-15 | Intervet Inc. | Vaccination with replicon particles and oil adjuvant |
MX2020006343A (es) | 2017-12-20 | 2020-09-03 | Intervet Int Bv | Diluyente mejorado para vacuna de herpesvirus alfa asociado con celulas. |
-
2021
- 2021-09-06 CN CN202180054946.4A patent/CN116528893A/zh active Pending
- 2021-09-06 EP EP21773074.6A patent/EP4210740A1/en active Pending
- 2021-09-06 US US18/043,944 patent/US20240024456A1/en active Pending
- 2021-09-06 WO PCT/EP2021/074446 patent/WO2022049276A1/en active Application Filing
- 2021-09-06 JP JP2023515018A patent/JP2023539771A/ja active Pending
- 2021-09-06 KR KR1020237011955A patent/KR20230065321A/ko unknown
- 2021-09-06 CA CA3190070A patent/CA3190070A1/en active Pending
- 2021-09-06 MX MX2023002674A patent/MX2023002674A/es unknown
- 2021-09-06 BR BR112023004123A patent/BR112023004123A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023004123A2 (pt) | 2023-04-04 |
WO2022049276A1 (en) | 2022-03-10 |
JP2023539771A (ja) | 2023-09-19 |
EP4210740A1 (en) | 2023-07-19 |
KR20230065321A (ko) | 2023-05-11 |
US20240024456A1 (en) | 2024-01-25 |
CA3190070A1 (en) | 2022-03-10 |
CN116528893A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013004303A (es) | Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral. | |
Wu et al. | Comparative genomic analysis of duck enteritis virus strains | |
HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
AR071910A1 (es) | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. | |
Boyd et al. | Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus | |
US9901632B2 (en) | Human herpesvirus immunotherapy | |
BR112015021974A2 (pt) | Composição, e, método de indução de uma resposta imune | |
MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
PH12015501378B1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
CO6140071A2 (es) | Poxvirus de mapache que expresa glicoproteinas de la rabia | |
Cheng et al. | Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1 | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
Wohlbold et al. | An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13 | |
Li et al. | Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail | |
Di Pilato et al. | Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression | |
MX2023002674A (es) | Vacuna del tallo de ha para blancos positivos a anticuerpos ha. | |
Maamary et al. | Attenuated influenza virus construct with enhanced hemagglutinin protein expression | |
BRPI0904020B8 (pt) | composição vacinal contra o vírus da dengue, e, kit | |
JP2018525028A5 (es) | ||
WO2019029081A1 (zh) | 干扰素κ在制备抗囊膜病毒药物方面的应用 | |
EP3715459B1 (en) | H9 avian influenza vaccine strain which differentiates infected from vaccinated animals, and preparation method therefor | |
BR112017024283A8 (pt) | Vacinas contra a dengue | |
Avanthay et al. | NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells | |
JP6373601B2 (ja) | アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド |